Stephen J Kanes MD
Assistant Professor, Department of Psychology, University of Pennsylvania
Join to view full profile
3400 Spruce StPhiladelphia, PA 19104
Phone+1 215-662-3511
Dr. Kanes is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Yale-New Haven Medical CenterResidency, Psychiatry, 1995 - 1999
Stony Brook University Health Sciences Center School of MedicineClass of 1995
Certifications & Licensure
PA State Medical License 1999 - 2018
CT State Medical License 1997 - 2017
Clinical Trials
- Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
- Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
- Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus Start of enrollment: 2014 Mar 21
Publications & Presentations
PubMed
- 22 citationsEfficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.Sagar V Parikh, Scott T Aaronson, Sanjay J Mathew, Gustavo Alva, Charles DeBattista
Neuropsychopharmacology. 2024-01-01 - 56 citationsZuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.Anita H Clayton, Robert Lasser, Sagar V Parikh, Dan V Iosifescu, JungAh Jung
The American Journal of Psychiatry. 2023-09-01 - 52 citationsZuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.Anita H Clayton, Robert Lasser, Indrani Nandy, Abdul J Sankoh, Jeffrey Jonas
The Journal of Clinical Psychiatry. 2023-02-20
Authored Content
- S100. Efficacy and Safety of Brexanolone IV Across Phase 2/3 Studies: A First-in-Class GABAA Receptor Positive Allosteric Modulator for Postpartum DepressionApril 2018
- S100. Efficacy and Safety of Brexanolone IV Across Phase 2/3 Studies: A First-in-Class GABAA Receptor Positive Allosteric Modulator for Postpartum DepressionApril 2018
Press Mentions
Shit Happens with the a TeamSeptember 16th, 2022- Brexanolone: A Possible Novel Treatment in Severe Postpartum DepressionJuly 13th, 2017
Grant Support
- Olfaction: A Novel Mouse Model Of SchizophreniaNational Institute Of Mental Health2003–2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
